Intriguingly, researchers have dissected that expansion of CTHRC1+ pathological lung fibroblasts resulted in rapidly progressing pulmonary fibrosis in patients with COVID-1955, indicating that CTHRC1 might be identified as a novel potential therapeutic target for COVID19 in the future. Here, CTHRC1 is linked to COVID-19.